Risk factors for and management of cognitive dysfunction in multiple sclerosis

Nature Reviews Neurology

Volumn 7, Issue 6, 2011, Pages 332-342

  Benedict, Ralph H B ^a   Zivadinov, Robert ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DONEPEZIL; HLA DR15 ANTIGEN; METHYLPHENIDATE; MODAFINIL; RIVASTIGMINE;

APOLIPOPROTEIN E GENE; ATTITUDE TO HEALTH; BEHAVIOR THERAPY; BRAIN ATROPHY; BRIEF REPEATABLE BATTERY TEST; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE RESERVE; COMORBIDITY; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GENE; GENETIC VARIABILITY; GRAY MATTER; HEREDITY; HUMAN; INTELLIGENCE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE;

APOLIPOPROTEINS E; BRAIN; COGNITION; COGNITION DISORDERS; COGNITIVE RESERVE; DISEASE PROGRESSION; HUMANS; INDIVIDUALITY; INTELLIGENCE; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79958223011     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.61     Document Type: Review

References (159)

1. Hauser, S. L., Oksenberg, J. R., Hauser, S. L. & Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52, 61-76 (2006). (Pubitemid 44466355)
2. Charcot, J. M. Lectures on the Diseases of the Nervous System (New Sydenham Society, London, 1877).
3. Rao, S. M., Leo, G. J., Bernardin, L. & Unverzagt, F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41, 685-691 (1991).
4. [No authors listed] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
5. Jacobs, L. D., et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exascerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult. Scler. 1, 118-135 (1995).
6. Johnson, K. P., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50, 701-708 (1998).
7. Amato, M. P., Zipoli, V. & Portaccio, E. Multiple-sclerosis related cognitive changes: a review of cross-sectional and longitudinal studies. J. Neurol. Sci. 245, 41-46 (2006). (Pubitemid 43775956)
8. Benedict, R. H. B., et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin. Neuropsychol. 16, 381-397 (2002). (Pubitemid 36390381)
9. Chiaravalloti, N. D. & DeLuca, J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 7, 1139-1151 (2008).
10. Patti, F. Cognitive impairment in multiple sclerosis. Mult. Scler. 15, 2-8 (2009).
11. Patti, F., et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult. Scler. 15, 779-788 (2009).
12. Benedict, R. H. B., et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 12, 549-558 (2006). (Pubitemid 44070305)
13. Carone, D., Benedict, R. H. B., Munschauer, F. E. III, Fishman, I. & Weinstock-Guttman, B. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J. Int. Neuropsychol. Soc. 11, 574-583 (2005). (Pubitemid 41478990)
14. Wechsler, D. Wechsler Adult Intelligence Scale, 4th edn (Pearson, New York, 2008).
15. Lezak, M. Neuropsychological Assessment (Oxford University Press, New York, 1995).
16. DeLuca, J., Chelune, G. J., Tulsky, D. S., Lengenfelder, J. & Chiaravalloti, N. D. Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J. Clin. Exp. Neuropsychol. 26, 550-562 (2004). (Pubitemid 39318348)
17. Archibald, C. J. & Fisk, J. D. Information processing efficiency in patients with multiple sclerosis. J. Clin. Exp. Neuropsychol. 22, 686-701 (2000).
18. Rao, S. M. On the nature of memory disturbance in multiple sclerosis. J. Clin. Exp. Neuropsychol. 11, 699-712 (1989). (Pubitemid 19271848)
19. DeLuca, J., Gaudino, E. A., Diamond, B. J., Christodoulou, C. & Engel, R. A. Acquisition and storage deficits in multiple sclerosis. J. Clin. Exp. Neuropsychol. 20, 376-390 (1998). (Pubitemid 28539557)
20. Kalmar, J. H., Gaudino, E. A., Moore, N. B., Halper, J. & Deluca, J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology 22, 442-449 (2008). (Pubitemid 351992891)
21. Langdon, D. W. & Thompson, A. J. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult. Scler. 5, 94-100 (1999). (Pubitemid 29186826)
22. Rao, S. M., et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41, 692-696 (1991).
23. Benedict, R. H. B., et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J. Neurol. Sci. 231, 29-34 (2005). (Pubitemid 40432023)
24. Buschke, F. & Fuld, P. A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24, 1019-1025 (1974).
25. Barbizet, J. & Cany, E. Clinical and psychometric study of a patient with memory disturbances. Int. J. Neurol. 7, 44-54 (1968).
26. Benton, A. L. & Hamsher, K. Multilingual Aphasia Examination (AJA Associates, Iowa City, 1989).
27. Borkowski, J. G., Benton, A. L. & Spreen, O. Word fluency and brain damage. Neuropsychologia 5, 135-140 (1967).
28. Gronwall, D. M. A. Paced auditory serial addition task: a measure of recovery from concussion. Percept. Mot. Skills 44, 367-373 (1977). (Pubitemid 8087310)
29. Rao, S. M. Neuropsychological Screening Battery for Multiple Sclerosis (National Multiple Sclerosis Society, New York, 1991).
30. Smith, A. Symbol Digit Modalities Test: Manual (Western Psychological Services, Los Angeles, 1982).
31. Huijbregts, S. C., Kalkers, N. F., de Sonneville, L. M., de Groot, V. & Polman, C. H. Cognitive impairment and decline in different MS subtypes. J. Neurol. Sci. 245, 187-194 (2006). (Pubitemid 43775947)
32. Christodoulou, C., et al. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 60, 1793-1798 (2003). (Pubitemid 36737076)
33. Amato, M. P., et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63, 89-93 (2004). (Pubitemid 38943784)
34. Camp, S. J., et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 128, 2891-2898 (2005). (Pubitemid 41746642)
35. Sepulcre, J., et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult. Scler. 12, 187-195 (2006).
36. Portaccio, E., et al. Reliability, practice effects, and change indices for Raos Brief Repeatable Battery. Mult. Scler. 16, 611617 (2010).
37. Peyser, J. M., Rao, S. M., LaRocca, N. G. & Kaplan, E. Guidelines for neuropsychological research in multiple sclerosis. Arch. Neurol. 47, 94-97 (1990). (Pubitemid 20024163)
38. Benedict, R. H. B., Schretlen, D., Groninger, L., Dobraski, M. & Shpritz, B. Revision of the Brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol. Assess. 8, 145-153 (1996). (Pubitemid 26236038)
39. Benedict, R. H. B. Brief Visuospatial Memory Test-Revised: Professional Manual (Psychological Assessment Resources, Odessa, FL, 1997).
40. Delis, D. C., Kramer, J. H., Kaplan, E. & Ober, B. A. California Verbal Learning Test Manual: Second Edition, Adult Version (Psychological Corporation, San Antonio, TX, 2000).
41. Delis, D. C., Kaplan, E. & Kramer, J. H. Delis-Kaplan Executive Function System (Psychological Corporation, San Antonio, TX, 2001).
42. Benton, A. L., Sivan, A. B., Hamsher, K., Varney, N. R. & Spreen, O. Contributions to Neuropsychological Assessment (Oxford University Press, New York, 1994).
43. Strober, L., et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult. Scler. 15, 1077-1084 (2009).
44. Duquin, J. A., Parmenter, B. A. & Benedict, R. H. B. Influence of recruitment and participation bias on neuropsychological research among MS patients. J. Int. Neuropsychol. Soc. 14, 494-498 (2008). (Pubitemid 351560445)
45. Parmenter, B. A., et al. Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J. Clin. Exp. Neuropsychol. 29, 215-223 (2007).
46. Benedict, R. H. B. Effects of using same vs alternate form memory tests in short-interval, repeated assessment in multiple sclerosis. J. Int. Neuropsychol. Soc. 11, 727-736 (2005). (Pubitemid 41631486)
47. Simon, J. H., et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53, 139-148 (1999). (Pubitemid 29329662)
48. Camp, S. J., et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 122, 1341-1348 (1999). (Pubitemid 29324854)
49. Deloire, M. S., et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 519-526 (2005). (Pubitemid 40486577)
50. Huijbregts, S. C., et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 63, 335-339 (2004). (Pubitemid 38971136)
51. Nocentini, U., Giordano, A., Di Vincenzo, S., Panella, M. & Pasqualetti, P. The Symbol Digit Modalities Test-oral version: Italian normative data. Funct. Neurol. 21, 93-96 (2006).
52. Nocentini, U., et al. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 12, 77-87 (2006). (Pubitemid 43169241)
53. Parmenter, B. A., Testa, S. M., Schretlen, D. J., Weinstock-Guttman, B. & Benedict, R. H. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc. 16, 616 (2010).
54. Parmenter, B. A., Weinstock-Guttman, B., Garg, N., Munschauer, F. & Benedict, R. H. B. Screening for cognitive impairment in MS using the Symbol Digit Modalities Test. Mult. Scler. 13, 52-57 (2007). (Pubitemid 46152761)
55. Benedict, R. H. B., et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch. Neurol. 63, 1301-1306 (2006). (Pubitemid 44379833)
56. Bermel, R. A., Sharma, J., Tjoa, C. W., Puli, S. R. & Bakshi, R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J. Neurol. Sci. 208, 57-65 (2003). (Pubitemid 36294155)
57. Benedict, R. H., Ramasamy, D., Munschauer, F., Weinstock-Guttman, B. & Zivadinov, R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J. Neurol. Neurosurg. Psychiatry 80, 201-206 (2009).
58. Tekok-Kilic, A., et al. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 36, 1294-1300 (2007). (Pubitemid 47007715)
59. Benedict, R. H. B., et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult. Scler. 13, 722-730 (2007). (Pubitemid 47074094)
60. Benedict, R. H. B., et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am. J. Neuroradiol. 26, 1824-1831 (2005). (Pubitemid 43853687)
61. Benedict, R. H. B., Carone, D. & Bakshi, R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J. Neuroimaging 14 (Suppl. 3), 36S-45S (2004). (Pubitemid 38781410)
62. Benedict, R. H. B., et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch. Neurol. 61, 226-230 (2004). (Pubitemid 38197556)
63. Drake, A. S., et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult. Scler. 16, 228237 (2010).
64. Fischer, J. S., Rudick, R. A., Cutter, G. R. & Reingold, S. C. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 5, 244-250 (1999). (Pubitemid 29405620)
65. Rosti, E., Hamalainen, P., Koivisto, K. & Hokkanen, L. PASAT in detecting cognitive impairment in relapsing-remitting MS. Appl. Neuropsychol. 14, 101-112 (2007). (Pubitemid 47041910)
66. Bever, C., Grattan, L., Panitch, H. S. & Johnson, K. P. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult. Scler. 1, 165-169 (1995).
67. Benedict, R. H. B., et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult. Scler. 14, 940-946 (2008).
68. Morrow, S. A., et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult. Scler. 16, 13851392 (2010).
69. Morrow, S. A., Jurgensen, S., Forrestal, F. & Benedict, R. H. B. Effects of acute relapses on neuropsychological status in multiple sclerosis patients. J. Neurol. doi:10.1007/s00415-011-5975-5973.
70. Morrow, S. A., et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist 24, 11311145 (2010).
71. Bodling, A. M., Denney, D. R. & Lynch, S. G. Cognitive aging in patients with multiple sclerosis: a cross-sectional analysis of speeded processing. Arch. Clin. Neuropsychol. 24, 761-767 (2009).
72. Amato, M. P., Ponziani, G., Siracusa, G. & Sorbi, S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol. 58, 1602-1606 (2001). (Pubitemid 32963224)
73. Amato, M. P., et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 75, 11341140 (2010).
74. Beatty, W. W. & Aupperle, R. L. Sex differences in cognitive impairment in multiple sclerosis. Clin. Neuropsychol. 16, 472-480 (2002). (Pubitemid 36605802)
75. Savettieri, G., et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208-1214 (2004). (Pubitemid 39517923)
76. Marrie, R. A., Cutter, G., Tyry, T., Vollmer, T. & Campagnolo, D. Does multiple sclerosis-associated disability differ between races? Neurology 66, 12351240 (1235).
77. Arnett, P. A., Barwick, F. H. & Beeney, J. E. Depression in multiple sclerosis: review and theoretical proposal. J. Int. Neuropsychol. Soc. 14, 691-724 (2008).
78. Morrow, S. A., Weinstock-Guttman, B., Munschauer, F., Hojnacki, D. & Benedict, R. H. B. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult. Scler. 15, 998-1005 (2009).
79. Amato, M. P., et al. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J. Neurol. 253, 1054-1059 (2006). (Pubitemid 44441131)
80. Glanz, B. I., et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult. Scler. 13, 1004-1010 (2007). (Pubitemid 351541435)
81. Comi, G., et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J. Neurol. Sci. 132, 222-227 (1995).
82. Filippi, M., et al. Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neurol. 34, 324-328 (1994).
83. Fisher, E., Lee, J. C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255-265 (2008).
84. Hawkes, C. H. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult. Scler. 13, 610-615 (2007). (Pubitemid 46939526)
85. Pittas, F., et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J. Neurol. 256, 577-585 (2009).
86. Staff, N. P., Lucchinetti, C. F. & Keegan, B. M. Multiple sclerosis with predominant, severe cognitive impairment. Arch. Neurol. 66, 1139-1143 (2009).
87. Ghaffar, O. & Feinstein, A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 71, 164-169 (2008).
88. Messinis, L., Kyprianidou, A., Malefaki, S. & Papathanasopoulos, P. Neuropsychological deficits in long-term frequent cannabis users. Neurology 66, 737-739 (2006). (Pubitemid 43739832)
89. Chapman, B. P., Lyness, J. M. & Duberstein, P. Personality and medical illness burden among older adults in primary care. Psychosom. Med. 69, 277-282 (2007). (Pubitemid 46653081)
90. Schwartz, E. S., Chapman, B. P., Duberstein, P. R., Weinstock-Guttman, B. & Benedict, R. H. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment 18, 3949 (2011).
91. Benedict, R. H. B., et al. Cortical atrophy and personality in multiple sclerosis. Neuropsychology 22, 432-441 (2008). (Pubitemid 351992890)
92. Mahley, R. W. & Rall, S. C. Jr. Apolipoprotein E: far more than a lipid transport protein. Annu.Rev. Genomics Hum. Genet. 1, 507-537 (2000).
93. Enzinger, C., et al. Accelerated evolution of brain atrophy and black holes in MS patients with APOE-4. Ann. Neurol. 55, 563-569 (2004). (Pubitemid 38391974)
94. De Stefano, N., et al. Influence of apolipoprotein E 4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch. Neurol. 61, 536-540 (2004). (Pubitemid 38923743)
95. Horáková, D., et al. APOE 4-positive multiple sclerosis patients develop more gray matter and whole brain atrophy. a 4-year longitudinal study using the 15-year disease onset model. Fol. Biol. Praha 56, 242251 (2010).
96. Ghaffar, O. & Feinstein, A. APOE ?4 and cognitive dysfunction in multiple sclerosis: a review. J. Neuropsychiatry Clin. Neurosci. 22, 155165 (2010).
97. Oliveri, R. L., et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol. Scand. 100, 290-295 (1999). (Pubitemid 29482551)
98. Koutsis, G., et al. An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult. Scler. 15, 174-179 (2009).
99. Koutsis, G., et al. APOE ?4 is associated with impaired verbal learning in patients with MS. Neurology 68, 546-549 (2007).
100. Parmenter, B. A., Denney, D. R., Lynch, S. G., Middleton, L. S. & Harlan, L. M. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult. Scler. 13, 25-32 (2007). (Pubitemid 46152758)
101. Savettieri, G., et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J. Neurol. 251, 1208-1214 (2004). (Pubitemid 39517923)
102. Ghaffar, O., Reis, M., Pennell, N., OConnor, P. & Feinstein, A. APOE 4 and the cognitive genetics of multiple sclerosis. Neurology 74, 16111618 (2010).
103. Portaccio, E., et al. ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol. Scand. 120, 439-441 (2009).
104. van der Walt, A., et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 73, 1018-1025 (2009).
105. Jensen, C. J., et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS ONE 5, e10003 (2010).
106. Zivadinov, R., et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain derived neurotrophic factor (BDNF). Hum. Mol. Genet. 16, 2659-2668 (2007). (Pubitemid 350018508)
107. Weinstock-Guttman, B., et al. The rs2030324 SNP of brain derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology 18, 4352 (2010).
108. Cerasa, A., et al. The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study. Behav. Brain Res. 207, 377386 (2010).
109. Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9, 516-526 (2008). (Pubitemid 351861542)
110. Fazekas, F., et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 53, 448-456 (1999). (Pubitemid 29382034)
111. Bakshi, R., Caruthers, S. D., Janardhan, V. & Wasay, M. Intraventricular CSF pulsation artifact on fast fluid-attenuated inversion-recovery MR images: analysis of 100 consecutive normal studies. AJNR Am. J. Neuroradiol. 21, 503-508 (2000). (Pubitemid 30149342)
112. Bakshi, R., Ariyaratana, S., Benedict, R. H. & Jacobs, L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch. Neurol. 58, 742-748 (2001). (Pubitemid 32423046)
113. Truyen, L., et al. Accumulation of hypointense lesions (black holes) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47, 1469-1476 (1996). (Pubitemid 26422538)
114. Zivadinov, R. & Bakshi, R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front. Biosci. 9, 665-683 (2004). (Pubitemid 39043742)
115. Rao, S. M., Leo, G. J., Haughton, V. M., Aubin-Faubert, P. S. & Bernardin, L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 39, 161-166 (1989). (Pubitemid 19059298)
116. Geurts, J. J., et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 236, 254-260 (2005). (Pubitemid 40853320)
117. Geurts, J. J., et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am. J. Neuroradiol. 26, 572-527 (2005).
118. Bagnato, F., et al. T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult. Scler. 16, 12031212 (2010).
119. Roosendaal, S. D., et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult. Scler. 15, 708-714 (2009).
120. McDonald, W. I., Miller, D. H. & Barnes, D. The pathological evolution of multiple sclerosis. Neuropathol. Appl. Neurobiol. 18, 319-334 (1992).
121. Trapp, B. D., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998). (Pubitemid 28065253)
122. Trapp, B. D., Ransohoff, R. & Rudick, R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295-302 (1999). (Pubitemid 29378163)
123. Peterson, J. W., Bö, L., Mörk, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389-400 (2001). (Pubitemid 32848742)
124. van Buchem, M. A., et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 50, 1609-1617 (1998). (Pubitemid 28283225)
125. Comi, G., et al. Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64 (Suppl. 1), S21-S25 (1998). (Pubitemid 28274432)
126. Filippi, M., et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68, 157-161 (2000). (Pubitemid 30245837)
127. Rovaris, M., et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J. Neurol. Sci. 195, 103-109 (2002). (Pubitemid 34202286)
128. Rudick, R. A., Fisher, E., Lee, J. C., Simon, J. & Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698-1704 (1999). (Pubitemid 29530342)
129. Hohol, M. J., et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch. Neurol. 54, 1018-1025 (1997). (Pubitemid 27330411)
130. Houtchens, M. K., et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 69, 113-123 (2007).
131. Benedict, R. H. B., et al. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 14, 44-51 (2002). (Pubitemid 34117022)
132. Anderson, V. M., et al. Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study. Mult. Scler. 16, 10831090 (2010).
133. Sicotte, N. L., et al. Regional hippocampal atrophy in multiple sclerosis. Brain 131, 1134-1141 (2008). (Pubitemid 351499428)
134. Feinstein, A., et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62, 586-590 (2004). (Pubitemid 38252800)
135. Stern, Y., et al. Influence of education and occupation on the incidence of Alzheimers disease. JAMA 271, 1004-1010 (1994). (Pubitemid 24099921)
136. Stern, Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, S69-S74 (2006). (Pubitemid 44265854)
137. Mainero, C., et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 21, 858-867 (2004). (Pubitemid 38314947)
138. Chiaravalloti, N., et al. Cerebral activation patterns during working memory performance in multiple sclerosis using fMRI. J. Clin. Exp. Neuropsychol. 27, 33-54 (2005). (Pubitemid 40392831)
139. Sumowski, J. F., Chiaravalloti, N., Wylie, G. & Deluca, J. Cognitive reserve moderates the negative effect of brain atrophy on cognitive effi ciency in multiple sclerosis. J. Int. Neuropsychol. Soc. 15, 606-612 (2009).
140. Sumowski, J. F., Wylie, G. R., Gonnella, A., Chiaravalloti, N. & Deluca, J. Premorbid cognitive leisure independently contributes to cognitive reserve in multiple sclerosis. Neurology 75, 14281431 (2010).
141. Sumowski, J. F., Wylie, G. R., Deluca, J. & Chiaravalloti, N. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain 133, 362374 (2010).
142. OBrien, A. R., Chiaravalloti, N., Goverover, Y. & Deluca, J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch. Phys. Med. Rehabil. 89, 761-769 (2008). (Pubitemid 351406321)
143. Chiaravalloti, N. D., DeLuca, J., Moore, N. B. & Ricker, J. H. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult. Scler. 11, 58-68 (2005). (Pubitemid 40259976)
144. Waxman, S. G. Membranes, myelin, and the pathophysiology of multiple sclerosis. N. Engl. J. Med. 306, 1529-1533 (1982).
145. Bever, C. T. Jr, et al. Treatment with oral 3, 4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47, 1457-1462 (1996).
146. Bever, C. T. Jr, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054-1059 (1994).
147. Rossini, P. M., et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7, 354-358 (2001). (Pubitemid 33138344)
148. Geisler, M. W., et al. The effects of amantadine and pemoline on cognitive funcitoning in multiple sclerosis. Arch. Neurol. 53, 185-188 (1996). (Pubitemid 26055267)
149. Wilken, J. A., et al. Treatment of multiple sclerosis related cognitive problems with adjunctive modafinil: Rationale and preliminary supportive data. Int. J. MS Care 10, 1-10 (2008).
150. Harel, Y., Appleboim, N., Lavie, M. & Achiron, A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J. Neurol. Sci. 276, 38-40 (2009).
151. Benedict, R. H., et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J. Neurol. 255, 848-852 (2008).
152. Morrow, S. A., et al. The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J. Neurol. 256, 1095-1102 (2009).
153. Krupp, L. B., et al. Donepezil improves memory in multiple sclerosis in a randomized clinical trial. Neurology 63, 1579-1585 (2004). (Pubitemid 39507572)
154. Krupp, L., et al. A multi-center randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (in press).
155. Shaygannejad, V., Janghorbani, M., Ashtari, F., Zanjani, H. A. & Zakizade, N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can. J. Neurol. Sci. 35, 476-481 (2008).
156. Sumoski, J. F., et al. l-amphetamine improves memory in MS patients with objective memory impairment. Mult. Scler. (in press).
157. Benedict, R. & Bobholz, J. Multiple sclerosis. Semin. Neurol. 27, 78-86 (2007).
158. Chapman, B. P., Duberstein, P. & Lyness, J. M. The distressed personality type: replicability and general health associations. Eur. J. Personality (2007).
159. Smits, R. C., et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44, 1701-1705 (1994). (Pubitemid 24286651)